Alkermes plc ALKS
44.94 USD -1.24 (-2.69%)
Regular-session close
44.94 0.00 0.00%
After hours · Nov 20, 5:31 PM ET
44.83 Day range 46.89
27.20 52-week range 55.22
- YTD
- +60.61%
- 1 year
- +59.42%
News
defenseworld.net Bessemer Group Inc. Acquires 202,616 Shares of Alkermes plc $ALKS Bessemer Group Inc. grew its stake in shares of Alkermes plc (NASDAQ: ALKS) by 129.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor…
defenseworld.net Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead Alkermes (NASDAQ: ALKS) is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected…
marketbeat.com Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead Alkermes NASDAQ: ALKS is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected…
businesswire.com Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall…benzinga.com RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $57 RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $56 to $57.
benzinga.com Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $68 Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $65 to $68.
benzinga.com HC Wainwright & Co. Maintains Neutral on Alkermes, Raises Price Target to $50 HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $43 to $50.
seekingalpha.com Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson -…
marketbeat.com What Alkermes (ALKS) Said on Its Q3 Earnings Call Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development…
zacks.com Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Alkermes Q3 2026 Earnings Call Transcript Alkermes (NASDAQ:ALKS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.benzinga.com Alkermes Q3 EPS $0.09 Beats $(0.06) Estimate, Sales $480.100M Beat $463.606M Estimate Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.06) by 250 percent. This is a 81.63 percent decrease over earnings of $0.49 per…
benzinga.com Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.822B Est Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.822 billion estimate.
businesswire.com Alkermes plc Reports Third Quarter 2026 Financial Results DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and…
defenseworld.net Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
businesswire.com Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
seekingalpha.com Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but…
defenseworld.net Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V. Robeco Institutional Asset Management B.V. trimmed its position in Alkermes plc (NASDAQ: ALKS) by 37.6% in the third quarter, according to the company in its most recent Form 13F filing with the…
gurufocus.com Alkermes to Report Third Quarter Financial Results on November 3, 2026 [url="]Alkermes plc[/url] (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to di
businesswire.com Alkermes to Report Third Quarter Financial Results on November 3, 2026 DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third…
zacks.com Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue State of Alaska Department of Revenue lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 43.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The…
businesswire.com Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the…
zacks.com 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
seekingalpha.com Stock Picks From Seeking Alpha's September 2026 New Analysts Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital…
